Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Publication Year: 2012

DOI:
10.1007/s00535-012-0673-1

PMCID:
PMC3541931

PMID:
23090001

Journal Information

Full Title: J Gastroenterol

Abbreviation: J Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest Toshiyuki Matsui received research grants from Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Ajinomoto Pharmaceuticals Co., Ltd., Zeria Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Astellas Pharma Inc.; received lecture fees from Eisai Co., Ltd., ABBOTT JAPAN Co., Ltd. Mamoru Watanabe received research grants from ABBOTT JAPAN Co., Ltd, Astellas Pharma Inc., Asahi Kasei Kuraray Medical Co., Ltd, Ajinomoto Pharmaceuticals Co., Ltd, AstraZeneca, Chugai Pharmaceutical Co., Ltd, DAIICHI SANKYO CO., Ltd., Eisai Co., Ltd, Kyowa Hakko Kirin Co., Ltd, Kyorin Pharmaceutical Co. Ltd, JIMRO Co., Ltd, Mitsubishi Tanabe Pharma Co., MSD K.K., Otsuka Pharma Co., Ltd, UCB Japan Co., Ltd, and Zeria Pharmaceutical Co., Ltd. Toshifumi Hibi serves as a consultant to Mitsubishi Tanabe Pharma Co.; Toshifumi Hibi received research grants from Abbott Japan Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ajinomoto Pharmaceuticals Co., Ltd., Zeria Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Asahi Kasei Kuraray Medical Co., Ltd., and AstraZeneca. Fumiaki Ueno and Katsuyoshi Matsuoka have no conflict of interest."

Evidence found in paper:

"This study was supported by the Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025